Synthetic biology has long been touted as a revolution in the bio-based materials and chemicals space. However, in spite of considerable promise, developers have had difficulties translating lab results to commercialization. Nevertheless, synthetic biology companies rank as the three highest VC funded companies in 2016. Unlike previous developers, who focused on the entire value chain from strain development to commercial scale production, newer companies have tightened focus to aid on individual steps within strain development. In light of this changing synthetic biology landscape, this report highlights promising players and outlines partnership strategies.
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 (0) 20-3460840
For APAC (Singapore)